Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

515 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of RPL39 in Metaplastic Breast Cancer.
Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC. Dave B, et al. Among authors: miller kd. J Natl Cancer Inst. 2016 Dec 31;109(6):djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun. J Natl Cancer Inst. 2016. PMID: 28040796 Free PMC article.
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100. Schneider BP, et al. Among authors: miller kd. J Clin Oncol. 2008 Oct 1;26(28):4672-8. doi: 10.1200/JCO.2008.16.1612. J Clin Oncol. 2008. PMID: 18824714 Free PMC article. Clinical Trial.
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.
Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Schneider BP, et al. Among authors: miller kd. Clin Cancer Res. 2013 Mar 1;19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22. Clin Cancer Res. 2013. PMID: 23340303 Free PMC article. Clinical Trial.
Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.
Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Schneider BP, et al. Among authors: miller kd. Br J Cancer. 2014 Sep 9;111(6):1241-8. doi: 10.1038/bjc.2014.430. Epub 2014 Aug 12. Br J Cancer. 2014. PMID: 25117820 Free PMC article. Clinical Trial.
Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103.
Schneider BP, Shen F, Jiang G, O'Neill A, Radovich M, Li L, Gardner L, Lai D, Foroud T, Sparano JA, Sledge GW Jr, Miller KD. Schneider BP, et al. Among authors: miller kd. JCO Precis Oncol. 2017;2017:PO.17.00059. doi: 10.1200/PO.17.00059. Epub 2017 Aug 21. JCO Precis Oncol. 2017. PMID: 29333527 Free PMC article.
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA, Chen YH, Solzak JP, Ahmad MN, Wedge DC, Brinza D, Scafe C, Veitch J, Gottimukkala R, Short W, Atale RV, Ivan M, Badve SS, Schneider BP, Lu X, Miller KD, Radovich M. Hancock BA, et al. Among authors: miller kd. Breast Cancer Res. 2019 Aug 5;21(1):87. doi: 10.1186/s13058-019-1171-7. Breast Cancer Res. 2019. PMID: 31383035 Free PMC article.
515 results